EUVIMED · CrossrefZeitschrift
Journal of Comparative Effectiveness Research
ISSN 2042-6305 · Becaris Publishing Limited
Neueste Artikel
Long-term economic benefits of early cancer detection through enhanced multimodal screening: a modeling study of whole-body MRI and liquid biopsy
Efficacy and safety of sepiapterin versus sapropterin in people living with phenylketonuria: a plain language summary of the AMPLIPHY trial
Disease perception, quality of life and mental health among Chinese patients with transplant-eligible newly diagnosed multiple myeloma following treatment: a cross-sectional survey study
Cost-effectiveness analysis of ribociclib plus an aromatase inhibitor versus abemaciclib plus endocrine therapy in the adjuvant treatment of HR+/HER2- early breast cancer: a Canadian payer perspective
Real-world utilization of pembrolizumab dosing schedules in Belgium: a multi-center retrospective study using a common data model and natural language processing
Letter to the Editor: Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema
Matching-adjusted indirect treatment comparisons in chronic inflammatory demyelinating polyneuropathy: interpreting current evidence and enhancing future studies
Expert panel agreement with large language model responses to uro-oncology guideline-based questions: insights from seven Delphi consensus panels across major urological cancers
Evaluation of large language models for guideline-based clinical questions in muscle-invasive and non-muscle-invasive bladder cancer and upper tract urothelial carcinoma: a multidisciplinary Delphi study
Evaluation of large language models for clinical decision support in penile and testicular cancer: a multidisciplinary Delphi study
Evaluation of large language models for clinical decision support in prostate cancer: a multidisciplinary Delphi study
Evaluation of large language models for clinical decision support in renal cell carcinoma: a multidisciplinary Delphi study
Methodological considerations for indirect treatment comparisons of HIV incidence for long-acting injectable pre-exposure prophylaxis
Considerations for understanding systematic reviews and network meta-analyses in neurological applications: a review and critique in chronic migraine
On the economics of broadly neutralizing monoclonal antibodies for HIV prevention in high-income countries
Comparative cost analysis of Eluvia™ versus Zilver ® PTX ® in treating femoropopliteal peripheral artery disease utilizing real-world data
Matching-adjusted indirect comparison of zanubrutinib and real-world chemotherapy, rituximab and chemoimmunotherapy in relapsed or refractory marginal zone lymphoma
Development and implementation of a living network meta-analysis framework for comparative effectiveness research: a case study in chronic venous insufficiency treatment
Real-world cost-effectiveness of sequential therapy of in-class transition to ixazomib versus daratumumab for transplant-ineligible newly diagnosed multiple myeloma in China
Response to Letter to the Editor regarding “Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema”
Will the UK–US pharmaceuticals deal really cause 229,000 excess deaths? A critical appraisal
Comparative efficacy and safety of olezarsen versus volanesorsen for familial chylomicronemia syndrome: a matching-adjusted indirect comparison
Indirect treatment comparison of iptacopan versus pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and residual anemia despite C5 inhibitor treatment
Effectiveness and safety of therapies for patients with opioid use disorder: a systematic review and network meta-analysis
Identification of treatment effect modifiers and prognostic factors in newly diagnosed and relapsed or refractory multiple myeloma
Confirmatory long-term efficacy and safety results of ataluren in patients with nmDMD from Study 041, an international, randomized, double-blind, placebo-controlled, Phase III trial
Matching-adjusted indirect comparison of ribociclib + nonsteroidal aromatase inhibitor versus abemaciclib + endocrine therapy in hormone receptor-positive/HER2-negative early breast cancer
Cost impact of Bruton’s tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia
Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-naïve people with HIV-1: a systematic literature review and network meta-analysis
Impact analysis of expanded access to ketamine for treatment-resistant depression
EUVIMED